| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer.
|
Cancer Immunol Immunother
|
2008
|
2.54
|
|
2
|
Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial.
|
J Clin Oncol
|
2009
|
1.44
|
|
3
|
Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer.
|
Clin Cancer Res
|
2009
|
1.27
|
|
4
|
Serum cytokine profiling as a diagnostic and prognostic tool in ovarian cancer: a potential role for interleukin 7.
|
Clin Cancer Res
|
2007
|
1.27
|
|
5
|
Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial.
|
Int J Cancer
|
2009
|
1.26
|
|
6
|
Lymphvascular space involvement: an independent prognostic factor in endometrial cancer.
|
Gynecol Oncol
|
2005
|
1.24
|
|
7
|
Five-year quality of life of endometrial cancer patients treated in the randomised Post Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial and comparison with norm data.
|
Eur J Cancer
|
2011
|
1.14
|
|
8
|
Molecular markers and clinical behavior of uterine carcinosarcomas: focus on the epithelial tumor component.
|
Mod Pathol
|
2011
|
1.01
|
|
9
|
Survival of ovarian cancer patients overexpressing the tumour antigen p53 is diminished in case of MHC class I down-regulation.
|
Gynecol Oncol
|
2008
|
1.00
|
|
10
|
The prognostic role of classical and nonclassical MHC class I expression in endometrial cancer.
|
Int J Cancer
|
2010
|
0.95
|
|
11
|
Distinct regulation and impact of type 1 T-cell immunity against HPV16 L1, E2 and E6 antigens during HPV16-induced cervical infection and neoplasia.
|
Int J Cancer
|
2006
|
0.94
|
|
12
|
Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer: a single-arm phase II study.
|
Int J Cancer
|
2012
|
0.94
|
|
13
|
Preoperative serum squamous cell carcinoma antigen levels in clinical decision making for patients with early-stage cervical cancer.
|
J Clin Oncol
|
2005
|
0.93
|
|
14
|
Until which age should women be vaccinated against HPV infection? Recommendation based on cost-effectiveness analyses.
|
J Infect Dis
|
2011
|
0.93
|
|
15
|
Therapeutic vaccination against chronic hepatitis C virus infection.
|
Antiviral Res
|
2012
|
0.92
|
|
16
|
Comparatively low attendance during Human Papillomavirus catch-up vaccination among teenage girls in the Netherlands: Insights from a behavioral survey among parents.
|
BMC Public Health
|
2012
|
0.91
|
|
17
|
Therapeutic immunization and local low-dose tumor irradiation, a reinforcing combination.
|
Int J Cancer
|
2013
|
0.89
|
|
18
|
Antitumor efficacy of wild-type p53-specific CD4(+) T-helper cells.
|
Cancer Res
|
2002
|
0.88
|
|
19
|
Addition of interferon-α to the p53-SLP® vaccine results in increased production of interferon-γ in vaccinated colorectal cancer patients: a phase I/II clinical trial.
|
Int J Cancer
|
2012
|
0.88
|
|
20
|
Antigen-specific immunotherapy in ovarian cancer and p53 as tumor antigen.
|
Curr Pharm Des
|
2012
|
0.87
|
|
21
|
Tumor-infiltrating cytotoxic T lymphocytes as independent prognostic factor in epithelial ovarian cancer with wilms tumor protein 1 overexpression.
|
J Immunother
|
2011
|
0.87
|
|
22
|
Molecular profiling of circulating tumor cells links plasticity to the metastatic process in endometrial cancer.
|
Mol Cancer
|
2014
|
0.87
|
|
23
|
Serum tryptophan and kynurenine concentrations as parameters for indoleamine 2,3-dioxygenase activity in patients with endometrial, ovarian, and vulvar cancer.
|
Int J Gynecol Cancer
|
2011
|
0.85
|
|
24
|
Potential target antigens for a universal vaccine in epithelial ovarian cancer.
|
Clin Dev Immunol
|
2010
|
0.85
|
|
25
|
C-type lectin-like molecule-1 (CLL1)-targeted TRAIL augments the tumoricidal activity of granulocytes and potentiates therapeutic antibody-dependent cell-mediated cytotoxicity.
|
MAbs
|
2015
|
0.84
|
|
26
|
Role of regulatory T-cells in immunization strategies involving a recombinant alphavirus vector system.
|
Antivir Ther
|
2011
|
0.84
|
|
27
|
Gynecologic examination and cervical biopsies after (chemo) radiation for cervical cancer to identify patients eligible for salvage surgery.
|
Int J Radiat Oncol Biol Phys
|
2006
|
0.84
|
|
28
|
The epidermal growth factor receptor pathway in relation to pelvic lymph node metastasis and survival in early-stage cervical cancer.
|
Hum Pathol
|
2010
|
0.83
|
|
29
|
Galectin-9 activates and expands human T-helper 1 cells.
|
PLoS One
|
2013
|
0.83
|
|
30
|
Natural history of high-grade cervical intraepithelial neoplasia: a review of prognostic biomarkers.
|
Expert Rev Mol Diagn
|
2015
|
0.83
|
|
31
|
Down-regulation of proteasomal subunit MB1 is an independent predictor of improved survival in ovarian cancer.
|
Gynecol Oncol
|
2009
|
0.83
|
|
32
|
Loss of HLA class I and mismatch repair protein expression in sporadic endometrioid endometrial carcinomas.
|
Int J Cancer
|
2012
|
0.82
|
|
33
|
Aromatase, cyclooxygenase 2, HER-2/neu, and p53 as prognostic factors in endometrioid endometrial cancer.
|
Int J Gynecol Cancer
|
2009
|
0.82
|
|
34
|
Antigen-specific active immunotherapy for ovarian cancer.
|
Cochrane Database Syst Rev
|
2010
|
0.82
|
|
35
|
Long-term clinical and immunological effects of p53-SLP® vaccine in patients with ovarian cancer.
|
Int J Cancer
|
2011
|
0.81
|
|
36
|
Equity in human papilloma virus vaccination uptake?: sexual behaviour, knowledge and demographics in a cross-sectional study in (un)vaccinated girls in the Netherlands.
|
BMC Public Health
|
2014
|
0.81
|
|
37
|
Prognostic role of indoleamine 2,3-dioxygenase in endometrial carcinoma.
|
Gynecol Oncol
|
2012
|
0.80
|
|
38
|
From tumor immunosuppression to eradication: targeting homing and activity of immune effector cells to tumors.
|
Clin Dev Immunol
|
2011
|
0.80
|
|
39
|
Radical surgery in patients with residual disease after (chemo)radiation for cervical cancer.
|
Int J Gynecol Cancer
|
2014
|
0.79
|
|
40
|
Heterologous prime-boost immunizations with a virosomal and an alphavirus replicon vaccine.
|
Mol Pharm
|
2010
|
0.79
|
|
41
|
Antigen-specific active immunotherapy for ovarian cancer.
|
Cochrane Database Syst Rev
|
2014
|
0.79
|
|
42
|
The epithelial polarity regulator LGALS9/galectin-9 induces fatal frustrated autophagy in KRAS mutant colon carcinoma that depends on elevated basal autophagic flux.
|
Autophagy
|
2015
|
0.78
|
|
43
|
Vaccine-based clinical trials in ovarian cancer.
|
Expert Rev Vaccines
|
2011
|
0.78
|
|
44
|
HPV-specific immunotherapy: key role for immunomodulators.
|
Anticancer Agents Med Chem
|
2014
|
0.77
|
|
45
|
Role of T cell competition in the induction of cytotoxic T lymphocyte activity during viral vector-based immunization regimens.
|
Vaccine
|
2010
|
0.77
|
|
46
|
Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.
|
BMC Infect Dis
|
2013
|
0.76
|
|
47
|
Role of endocervical curettage in the preoperative staging of endometrial carcinoma.
|
Gynecol Oncol
|
2009
|
0.76
|
|
48
|
Targeted delivery of CD40L promotes restricted activation of antigen-presenting cells and induction of cancer cell death.
|
Mol Cancer
|
2014
|
0.76
|
|
49
|
An overview of innovative techniques to improve cervical cancer screening.
|
Cell Oncol
|
2006
|
0.75
|
|
50
|
Less gastrointestinal toxicity after adjuvant radiotherapy on a small pelvic field compared to a standard pelvic field in patients with endometrial carcinoma.
|
Int J Gynecol Cancer
|
2012
|
0.75
|
|
51
|
Multimodality treatment warranted for ovarian cancer: immunotherapy, a prerequisite to improve prognosis for this vicious disease.
|
Immunotherapy
|
2009
|
0.75
|
|
52
|
Surgery for patients with newly diagnosed advanced ovarian cancer: which patient, when and extent?
|
Curr Opin Oncol
|
2017
|
0.75
|